================================================================================

                            SCHEDULE 14A INFORMATION
                   PROXY STATEMENT PURSUANT TO SECTION 14(a)
                     OF THE SECURITIES EXCHANGE ACT OF 1934


Filed by the Registrant [ ]
Filed by a Party other than the Registrant [X]
    Check the appropriate box:
     [ ]   Preliminary Proxy Statement
     [ ]   Confidential, for Use of the Commission only (as permitted by
           Rule 14a-6(e)(2))
     [ ]   Definitive Proxy Statement
     [ ]   Definitive Additional Materials
     [X]   Soliciting Material Under Rule 14a-12


                          NORTHFIELD LABORATORIES INC.

                (Name of Registrant as Specified in its Charter)

                                C. ROBERT COATES
                                ----------------

     (Name of Person(s) Filing Proxy Statement if other than the Registrant)


Payment of Filing Fee (Check the appropriate box):

[X]  No fee required.
[ ]  $125 per Exchange Act Rules 0-11(c)(1)(ii), 14a-6(i)(1), 14a-6(i)(2) or
     Item 22(a)(2) of Schedule 14A.
[ ]  Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
     1)     Title of each class of securities to which transaction applies:
     2)     Aggregate number of securities to which transaction applies:
     3)     Per unit price or other underlying value of transaction computed
            pursuant to Exchange Act Rule 0-11 (Set forth the amount on which
            the filing fee is calculated and state how it was determined):
     4)     Proposed maximum aggregate value of transaction:
     5)     Total fee
            paid:
[ ]  Fee paid previously with preliminary materials.
[ ]  Check box if any part of the fee is offset as provided by Exchange Act Rule
     0-11(a)(2) and identify the filing for which the offsetting fee was paid
     previously. Identify the previous filing by registration statement number,
     or the Form or Schedule and the date of its filing.
     1)     Amount Previously Paid:
     2)     Form, Schedule or Registration Statement No.:
     3)     Filing Party: C. Robert Coates
     4)     Date Filed: September 12, 2002


================================================================================


COATES   AND  WILLIAMS'  KEY  POINTS  ON  MAXIMIZING  THE  VALUE  OF  NORTHFIELD
LABORATORIES

MISSION:   Serve  the  shareholders. Maximize  the  value  of  shares.  Continue
improving corporate governance.

We  believe that Northfield's shares can sell for at least $20.  How do we  know
Northfield's shares could be worth at least $20? Northfield's announcement  that
it  was filing with the FDA and asking for fast track review and approval lifted
Northfield's share price to $21.25 on heavy volume on August 17, 2001, just  one
year  ago.  According to several studies, the costs of bringing a major new drug
or  biologic through Phase III and gaining FDA approval range from $500 to  $800
million.  No one we've talked to doubts the safety and efficacy of PolyHeme.  It
only  remains for Northfield to properly demonstrate this to the FDA.  So  these
studies suggest that Northfield shares could be worth between $36.75 and  $56.08
on a cost basis once PolyHeme is approved.

We  also  believe that Northfield's shares can potentially be worth far more  if
the company can be effectively managed as an independent entity.

Here are a number of actions that we think Northfield's management and directors
can take in the coming months to better serve all shareholders:

*   Find  a  major pharmaceutical company to partner with Northfield. NORTHFIELD
    NEEDS  A NEW CEO AND MONEY NOW. Northfield needs more money, and it needs  a
    CEO who can get the job done for the shareholders. We think the only way  to
    remedy the present situation is to partner with a major pharmaceutical  firm
    on  terms satisfactory to shareholders. In addition to infusing much  needed
    capital  into  the company before it runs out of money, this  pharmaceutical
    company  would  provide  Northfield with an  experienced  CEO  and  the  FDA
    regulatory, marketing and manufacturing expertise that is missing.

*   Provide for better disclosure of information to shareholders.

*   Ask Northfield to partner with companies to extend possible applications  of
    PolyHeme as a transport delivery mechanism for other drugs.

*   Work  with  the  Department of Defense and the Homeland Security  Agency  to
    explore  the possibility of stockpiling PolyHeme as a safe, effective  blood
    substitute for emergencies.

*   Gain representation on Northfield's board as independent directors.

*   Raise the profile of PolyHeme.

*   Hold management accountable for meeting realistic goals and budgets.  Do the
    same for directors.